Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation
Amphista Therapeutics, a leading company in next-generation targeted protein degradation (TPD), has published a study in Nature Communications demonstrating a novel mechanism for degrading the key cancer target BRD9 using their proprietary Targeted Glue small molecule degrader and DCAF16 E3 ligase.
"The deep expertise of our scientists led to the successful integration of the favorable performance characteristics of earlier generation PROTACs and conventional molecular glues but with key limitations designed-out." - Louise Modis, PhD, Chief Scientific Officer at Amphista Therapeutics
The study highlights the company's innovative approach to targeted protein degradation, showcasing the potential of their Targeted Glues technology.
Author's summary: Amphista Therapeutics publishes novel cancer target degradation mechanism.
More News
- It’s All About Dance Music as Dexter Community Band Kicks Off its 2025-26 Season - The Sun Times News
- Lightning place forward Mitchell Chaffee on waivers
- WEEK 10 SEMOBALL TOP 10: Dexter back up, St. Vincent sneaks forward
- GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate | PharmExec
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Frogs help Fred Hutch find the shape of small things
- First Duel Night Abyss Figure Is Based on Psyche
- State begins distributing disaster aid to residents of Western Alaska, federal aid also approved
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- LPD searches for motor vehicle theft suspect